14:12:47 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriLäkemedel & Handel
DanCann Pharma grundades 2018 och är ett danskt läkemedelsbioteknikbolag som drivs av cannabinoider. DanCann Pharma fokuserar på att upptäcka, utveckla, tillverka och kommersialisera nya cannabinoida läkemedel inom ett brett spektrum av sjukdomsområden. Bolaget tillverkar och distribuerar receptbelagda läkemedel och receptfria läkemedel (OTC), främst fokuserade på smärtpatienter med alternativa behov och hantering av sin sjukdom, täckta av det danska pilotprogrammet för medicinsk cannabis.

Kalender

2022-04-07 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-07-23 Extra Bolagsstämma 2021
2021-05-28 Kvartalsrapport 2021-Q1
2021-04-29 Ordinarie utdelning DANCAN 0.00 DKK
2021-04-28 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2021-10-04 19:25:38

COPENHAGEN, Denmark, 04 October 2021 - DanCann Pharma A/S ("DanCann" or the "Company") hereby announces its intention to carry out a new issue of units directed to Swedish and Danish investors, which is intended to be carried out based on the authorization granted by the extra general meeting on 23 July 2021 (the "Directed Issue"). DanCann has engaged Corpura Fondkommission AB ("Corpura") to investigate the conditions for the Directed Share Issue of units through an accelerated book building procedure, which commences after the publication of this press release.

The subscription price of the units will be determined through an accelerated book building procedure, which will begin immediately after the publication of this announcement and before the commencement of trading on Spotlight Stock Market on 05 October 2021. The book building procedure may, at the discretion of the Company, close earlier or later and may be cancelled at any time.

The reasons for the deviation from the shareholders' preferential rights are mainly to further diversify the shareholder base and at the same time, raise capital in a time-efficient manner. The Board of Directors' assessment is that the subscription price in the Directed Share Issue will be in accordance with market conditions, since it has been determined through an "accelerated book-building" procedure.

Advisers

Corpura Fondkommission AB is the financial advisor of DanCann Pharma in connection with the directed issue of units. Andersen Partners Advokatpartnerselskab is acting as legal advisor. For additional information about the directed issue of shares, please contact:

Corpura Fondkommission AB
E-mail: info@corpura.se
www.corpura.se

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company based in Denmark. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.
For more information, visit: www.dancann.com

For further information, please contact:

Jeppe Krog Rasmussen, CEO
E-mail: jkr@dancann.com
Website: www.dancann.com